PT  - JOURNAL ARTICLE
AU  - Powell, Annabel A
AU  - Ireland, Georgina
AU  - Leeson, Rebecca
AU  - Lacey, Andrea
AU  - Ford, Ben
AU  - Poh, John
AU  - Ijaz, Samreen
AU  - Shute, Justin
AU  - Cherepanov, Peter
AU  - Tedder, Richard
AU  - Bottomley, Christian
AU  - Dawe, Fiona
AU  - Mangtani, Punam
AU  - Jones, Peter
AU  - Nguipdop-Djomo, Patrick
AU  - Ladhani, Shamez
TI  - National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021
AID  - 10.1101/2022.07.20.22277838
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.20.22277838
4099  - http://medrxiv.org/content/early/2022/07/21/2022.07.20.22277838.short
4100  - http://medrxiv.org/content/early/2022/07/21/2022.07.20.22277838.full
AB  - Background Risk factors for infection and, therefore, antibody positivity rates will be different in children compared to adults. We aim to estimate national and regional prevalence of SARS-CoV-2 antibodies in primary (4-11-year-olds) and secondary (11-15-year-olds) school children between 10 November and 10 December 2021.Methods Cross-sectional surveillance in England using two stage sampling, firstly stratifying into regions and selecting local authorities, then selecting schools according to a stratified sample within selected local authorities. Participants were sampled using a novel oral fluid validated assay for SARS-CoV-2 spike and nucleocapsid IgG antibodies.Results 4,980 students from 117 state-funded schools (2,706 from 83 primary schools, 2,274 from 34 secondary schools) provided a valid sample. After weighting for age, sex and ethnicity, and adjusting for assay accuracy, the national prevalence of SARS-CoV-2 antibodies in primary school students, who were all unvaccinated, was 40.1% (95%CI; 37.3-43.0). Antibody prevalence increased with age (p<0.001) and were higher in urban than rural schools (p=0.01). In secondary school students, the adjusted, weighted national prevalence of SARS-CoV-2 antibodies was 82.4% (95%CI; 79.5-85.1); including 57.5% (95%CI; 53.9-61.1) in unvaccinated and 97.5% (95%CI; 96.1-98.5) in vaccinated students. Antibody prevalence increased with age (p<0.001), and was not significantly different in urban versus rural students (p=0.1).Conclusions Using a validated oral fluid assay, we estimated national and regional seroprevalence of SARS-CoV-2 antibodies in primary and secondary school students. In November 2021, 40% of primary school students and nearly all secondary school students in England had SARS-CoV2 antibodies through a combination of natural infection and vaccination.Competing Interest StatementConflict of interest: PC and RT have a patent on SARS-CoV-2 antibody detection assay; PC has a patent on modified SARS virus spike protein subunitClinical Protocols https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19schoolsinfectionsurvey2021to2022methodsandfurtherinformation Funding StatementThis study was funded by the UK Department of Health and Social Care. Work in PCs laboratory was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001061), the Wellcome Trust (FC001061), and the UK Medical Research Council (FC001061). The concept of capture assays was developed in collaboration with Imperial College London, UKRI CV220-11: Serological detection of past SARS-CoV-2 infection by non-invasive sampling for field epidemiology and quantitative antibody detection. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was granted approval (including ethical approval) by UKHSA Research Ethics and Governance Group on 2/11/2021, R&D ref: 474I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.support{at}ons.gov.uk or visit the SRS website.